AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21197542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO(3))
Number of subjects: 11
Study 21197542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CaCO(3))
Number of subjects: 11
Study 19281499 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus conventional medical management (CMM), n = 52
Number of subjects: 100
Study 19281499 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM) alone, n = 48
Number of subjects: 100
Study 17237134 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (up to 25 mg twice a day)
Number of subjects: 16
Study 17237134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14963054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-soluble fiber diet (0.4 g added soluble fiber/2800 kcal)
Number of subjects: 18
Study 14963054 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-soluble fiber diet (3 g added soluble fiber/2800 kcal)
Number of subjects: 18
Study 14963054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soluble fiber diet (6 g added soluble fiber/2800 kcal)
Number of subjects: 18
Study 14963054 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental diets
Number of subjects: 18
Study 14963054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soluble fiber diet
Number of subjects: 18
Study 11758955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m‐ECD SPECT
Number of subjects: 12
Study 11758955 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (NC group)
Number of subjects: 12
Study 8979210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills Therapy
Number of subjects: 1726
Study 8979210 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 1726
Study 8979210 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation Therapy
Number of subjects: 1726
Study 8979210 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation treatment
Number of subjects: 1726
Study 8979210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 1726
Study 8424548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 500
Study 8424548 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 500
Study 8424548 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 500
Study 8424548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 3662056 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 0.08 mg IV every 2 min
Number of subjects: 90
Study 3662056 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 2.5 mg IV every 2 min
Number of subjects: 90
Study 29530258 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided CBT via the Internet (ICBT)
Number of subjects: 92
Study 29530258 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 92
Study 29530258 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 92
Study 26620919 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant antithrombin
Number of subjects: 8
Study 26620919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 25541821 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 60
Study 25541821 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin: 500 mg once per day for 3 days + standard medical care
Number of subjects: 60
Study 25541821 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin: 500 mg once per day for 7 days, followed by 500 mg once per week for 12 weeks + standard medical care
Number of subjects: 60
Study 22823289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigroup item randomized response theory (MIRRT)
Number of subjects: 6195
Study 22823289 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRRT
Number of subjects: 6195
Study 20081092 — intervention group
Group type: COMPARATOR
Intervention: Urinary hepcidin (nanograms/milligram of urinary creatinine) in patients with iron deficiency and inflammation anemia
Number of subjects: 582
Study 20081092 — intervention group
Group type: COMPARATOR
Intervention: Urinary hepcidin
Number of subjects: 582
Study 20081092 — intervention group
Group type: COMPARATOR
Intervention: IL-6 and CRP levels
Number of subjects: 582
Study 20081092 — intervention group
Group type: COMPARATOR
Intervention: Proinflammatory markers (IL-6, CRP)
Number of subjects: 582
Study 18855352 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 139
Study 18855352 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin/Pravastatin
Number of subjects: 139
Study 15823180 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle energy metabolism in COPD patients
Number of subjects: 8
Study 15823180 — intervention group
Group type: COMPARATOR
Intervention: Calf muscle energy metabolism in control subjects
Number of subjects: 8
Study 12435217 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy products
Number of subjects: 29
Study 12435217 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone preparations
Number of subjects: 29
Study 12435217 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 29
Study 12435217 — intervention group
Group type: COMPARATOR
Intervention: Dong quai
Number of subjects: 29
Study 12435217 — intervention group
Group type: COMPARATOR
Intervention: Evening primrose oil
Number of subjects: 29
Study 12435217 — intervention group
Group type: COMPARATOR
Intervention: Chinese herb mixture
Number of subjects: 29
Study 12435217 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 29
Study 12435217 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 29
Study 12435217 — intervention group
Group type: COMPARATOR
Intervention: Red clover
Number of subjects: 29
Study 10353369 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic working memory task
Number of subjects: 12
Study 10353369 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological working memory task
Number of subjects: 12
Study 10353369 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic working memory task
Number of subjects: 12
Study 10353369 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 12
Study 10353369 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory tasks (semantic, phonological, orthographic)
Number of subjects: 12
Study 7867177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/h GTN skin patch
Number of subjects: 20
Study 7867177 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 20
Study 1431365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CFPM)
Number of subjects: 170
Study 1431365 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (CAZ)
Number of subjects: 170
Study 3969339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mL of ferrous sulfate (FeSO4) drops (about 3 mg of iron per kilogram per day) for 3 months
Number of subjects: 278
Study 3969339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume) for 3 months
Number of subjects: 278
Study 3969339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mL of ferrous sulfate (FeSO4) drops
Number of subjects: 278
Study 3969339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 30669918 — intervention group
Group type: EXPERIMENTAL
Intervention: Finned stem (FS)
Number of subjects: 54
Study 30669918 — intervention group
Group type: COMPARATOR
Intervention: I-beam block stem (IS)
Number of subjects: 54
Study 28913896 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical non-azole solution applied to one paw
Number of subjects: 18
Study 28913896 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the other paw
Number of subjects: 18
Study 24272062 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic ureterolithotomy (RPLU)
Number of subjects: 70
Study 24272062 — intervention group
Group type: COMPARATOR
Intervention: Open mini-incision ureterolithotomy (MIOU)
Number of subjects: 70
Study 24272062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RPLU and MIOU
Number of subjects: 70
Study 22124101 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) plus Bevacizumab (15 mg/kg) (CPB)
Number of subjects: 214
Study 22124101 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) (CP)
Number of subjects: 214
Study 22124101 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel plus Bevacizumab (CPB) in patients with elevated serum lactate dehydrogenase
Number of subjects: 214
Study 22124101 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus Paclitaxel (CP) in patients with elevated serum lactate dehydrogenase
Number of subjects: 214
Study 20808678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 89
Study 20808678 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 18254223 — intervention group
Group type: EXPERIMENTAL
Intervention: Longidase (3000 IU, 10 injections, once in 5 days)
Number of subjects: 0
Study 16003037 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar bracing
Number of subjects: 136
Study 16003037 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program with patellar bracing
Number of subjects: 136
Study 16003037 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 136
Study 16003037 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program with knee sleeve
Number of subjects: 136
Study 12638810 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of oral contraceptives (20 clients)
Number of subjects: 300
Study 12638810 — intervention group
Group type: COMPARATOR
Intervention: Standard provision of oral contraceptives (280 clients)
Number of subjects: 300
Study 9430262 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor D (beta-carotene, alpha-tocopherol (vitamin E), and selenium)
Number of subjects: 29584
Study 9430262 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin/mineral supplement (in a parallel trial)
Number of subjects: 29584
Study 8091822 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.75 mg/kg i.v.)
Number of subjects: 0
Study 8091822 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.075 mg/kg i.v.)
Number of subjects: 0
Study 8091822 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (oral administration over one week)
Number of subjects: 0
Study 8091822 — intervention group
Group type: COMPARATOR
Intervention: Gallopamil (Ca(++)-blocker)
Number of subjects: 0
Study 2834943 — intervention group
Group type: EXPERIMENTAL
Intervention: Red kidney beans
Number of subjects: 6
Study 2834943 — intervention group
Group type: COMPARATOR
Intervention: Bran cereal
Number of subjects: 6
Study 2834943 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated consumption (day 1 vs day 7)
Number of subjects: 6
Study 2834943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 6
Study 29878267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid
Number of subjects: 142
Study 29878267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.13 mg l-5-MTHF
Number of subjects: 142
Study 29878267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 28915914 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐TCP‐containing screw
Number of subjects: 80
Study 28915914 — intervention group
Group type: COMPARATOR
Intervention: pure PLLA screw
Number of subjects: 80
Study 26573847 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary reflexive pelvic floor muscle training in addition to standard training
Number of subjects: 96
Study 26573847 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy program
Number of subjects: 96
Study 24070102 — intervention group
Group type: EXPERIMENTAL
Intervention: Booking orders for spectacles with subsequent delivery
Number of subjects: 21
Study 24070102 — intervention group
Group type: EXPERIMENTAL
Intervention: On‐the‐spot fitting and dispensing of spectacles
Number of subjects: 21
Study 24070102 — intervention group
Group type: COMPARATOR
Intervention: Issued only a prescription
Number of subjects: 21
Study 24070102 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 21
Study 21397769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate/pravastatin 160/40 mg FDC
Number of subjects: 291
Study 21397769 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 291
Study 18988075 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers anticipating smoking-related pictures
Number of subjects: 24
Study 18988075 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers anticipating smoking-related pictures
Number of subjects: 24
Study 17015867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg)
Number of subjects: 29
Study 17015867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 29
Study 17015867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14557148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (n = 28)
Number of subjects: 97
Study 14557148 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet (n = 28)
Number of subjects: 97
Study 14557148 — intervention group
Group type: COMPARATOR
Intervention: Repeated assessments (n = 29)
Number of subjects: 97
Study 11095435 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione (ASD) three times daily
Number of subjects: 55
Study 11095435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8623961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg
Number of subjects: 136
Study 8623961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 8623961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.075 mg/kg
Number of subjects: 136
Study 1543677 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of terbinafine
Number of subjects: 4
Study 1543677 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of terbinafine
Number of subjects: 4
Study 1543677 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of terbinafine
Number of subjects: 4
Study 1543677 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of terbinafine
Number of subjects: 4
Study 1543677 — intervention group
Group type: EXPERIMENTAL
Intervention: N-demethylated metabolite
Number of subjects: 4
Study 3897535 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 10-20 mg once daily
Number of subjects: 140
Study 3897535 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75-125 mg in divided doses
Number of subjects: 140
Study 31079275 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin mini-tablets (PedPRM; 2–5 mg)
Number of subjects: 125
Study 31079275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 29282534 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) for 8 weeks
Number of subjects: 60
Study 29282534 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 27613521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 27613521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure everolimus
Number of subjects: 366
Study 27613521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exposure everolimus
Number of subjects: 366
Study 24695940 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral resection using microelectrodes
Number of subjects: 54
Study 22699730 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program in nursing (educational meetings, home visits, telenursing, printed book)
Number of subjects: 63
Study 22699730 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 63
Study 19995670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus bupropion
Number of subjects: 61
Study 19995670 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) plus placebo
Number of subjects: 61
Study 19995670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 61
Study 18565463 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, computer‐tailored intervention delivered on a CD‐ROM
Number of subjects: 442
Study 18565463 — intervention group
Group type: EXPERIMENTAL
Intervention: Print‐delivered, computer‐tailored intervention
Number of subjects: 442
Study 18565463 — intervention group
Group type: COMPARATOR
Intervention: Print‐delivered, generic information
Number of subjects: 442
Study 15517433 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (5000 mg per day)
Number of subjects: 160
Study 15517433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 12029811 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers who received incentives
Number of subjects: 7186
Study 12029811 — intervention group
Group type: COMPARATOR
Intervention: Volunteers who received no incentives
Number of subjects: 7186
Study 12029811 — intervention group
Group type: EXPERIMENTAL
Intervention: Male volunteers
Number of subjects: 7186
Study 12029811 — intervention group
Group type: EXPERIMENTAL
Intervention: Female volunteers
Number of subjects: 7186
Study 9889803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation of eschar with a rapidly scanned continuous wave carbon dioxide laser system, average energy of 99.2 ± 5.7 W.
Number of subjects: 21
Study 9889803 — intervention group
Group type: COMPARATOR
Intervention: Control wound sharply excised and autografted.
Number of subjects: 21
Study 7552480 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine sachets (250 mg or 167 mg twice daily for at least 1 month)
Number of subjects: 15
Study 7552480 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine chewable/dispersible tablets (200 mg or 125 mg after conversion from sachets)
Number of subjects: 15
Study 7552480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ddI (sachets, 167 mg; tablets, 125 mg)
Number of subjects: 15
Study 7552480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ddI (sachets, 250 mg; tablets, 200 mg)
Number of subjects: 15
Study 2288826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 12
Study 2288826 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 12
Study 2288826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (400 mg)
Number of subjects: 12
Study 2288826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6109568 — intervention group
Group type: EXPERIMENTAL
Intervention: Halazepam (80 to 160 mg)
Number of subjects: 64
Study 6109568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate (15 to 30 mg)
Number of subjects: 64
Study 6109568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6109568 — intervention group
Group type: EXPERIMENTAL
Intervention: Halazepam vs Clorazepate
Number of subjects: 64
Study 31714322 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/mL oxycodone plus 0.1% ropivacaine
Number of subjects: 80
Study 31714322 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 80
Study 31800987 — intervention group
Group type: EXPERIMENTAL
Intervention: POEM
Number of subjects: 221
Study 31800987 — intervention group
Group type: COMPARATOR
Intervention: LHM plus Dor's fundoplication
Number of subjects: 221
Study 27006419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (balance activities with cognitive tasks)
Number of subjects: 47
Study 27006419 — intervention group
Group type: COMPARATOR
Intervention: Single-task training (balance activities alone)
Number of subjects: 47
Study 27006419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (dual-task and single-task)
Number of subjects: 47
Study 25808188 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression at myofascial trigger points (MTrPs)
Number of subjects: 63
Study 25808188 — intervention group
Group type: COMPARATOR
Intervention: Compression at non-trigger points (non-MTrP)
Number of subjects: 63
Study 25808188 — intervention group
Group type: COMPARATOR
Intervention: Effleurage massage (superficial massage)
Number of subjects: 63
Study 23382637 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 40% wt/vol barium sulfate suspension before 3 mealtimes, 60 mL 60% diatrizoate meglumine diluted in 250 mL water after supper, and 10 mg bisacodyl enteric‐coated tablets 1 h before oral administration of 2 L PEG‐4000 electrolyte solution (Study Group A)
Number of subjects: 60
Study 23382637 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical treatment to Study Group A, but bisacodyl was given 1 h after oral PEG‐4000 (Study Group B)
Number of subjects: 60
Study 23382637 — intervention group
Group type: COMPARATOR
Intervention: Control group managed using the same strategy as Study Group A, but without administration of bisacodyl
Number of subjects: 60
Study 21372756 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (more intensive regimen)
Number of subjects: 1209
Study 21372756 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (less intensive regimen)
Number of subjects: 1209
Study 21372756 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 1209
Study 19214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (SQV/r) 1000 mg/100 mg twice a day
Number of subjects: 337
Study 19214123 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice a day
Number of subjects: 337
Study 19214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (SQV/r)
Number of subjects: 337
Study 19214123 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 337